ライフサイエンスコーパス: Medicare

1 been a target of financial penalties through Medicare.

2 plied by 5 to estimate use throughout all of Medicare.

3 rate (images per 1000 enrollees per year for Medicare: 17 [95% CI: 6, 28]; commercially insured patie

4 010s (images per 1000 enrollees per year for Medicare: -301 [95% CI: -510, -92]; commercially insured

5 among those with private insurance (48.2%), Medicare (53.4%), or government health insurance other t

6 dicaid recipients ($3) than among those with Medicare ($80) or commercial insurance ($107).

7 000s (images per 1000 enrollees per year for Medicare: 91 [95% confidence interval {CI}: 34, 148]; co

8 Medicare administrative claims were used to evaluate mor

9 re fee for service and $57 978+/-$29 431 for Medicare Advantage (mean hospital margin of -$30 828+/-$

10 -for-service beneficiaries and estimates for Medicare Advantage beneficiaries, we estimate the total

11 This study uses commercial and Medicare Advantage claims data to compare medication fil

12 and skilled nursing facility admissions for Medicare Advantage patients to have risen from $6.0 to $

13 experience of nontargeted, privately insured Medicare Advantage patients.

14 of Michigan/Blue Care Network commercial and Medicare Advantage plans undergoing CABG (n=11 208) or A

15 Patients with Medicare Advantage received fewer eye examinations at 5

16 ility admission for all (fee-for-service and Medicare Advantage) Medicare patients to have risen from

17 costs are not available for Medicare Part C (Medicare Advantage) patients.

18 are fee for service and -$6055+/-$45 033 for medicare advantage).

19 are fee for service national payments, while medicare advantage, hospital, and patient costs were der

20 icare fee for service, and $1658+/-$1250 for medicare advantage.

21 imary outcome was the change in standardized Medicare-allowed payments per 90-day episode.

22 a combination of postacute care and hospital Medicare-allowed payments.

23 ns were identified among 172 041 patients in Medicare and 58 279 observations among 44 118 patients i

24 ode definitions for NDI were applied to both Medicare and commercial claims, rates were calculated pe

25 rect comparison of utilization rates between Medicare and commercially insured patients.

26 s for all adults enrolled in fee-for-service Medicare and for roughly 9 million commercially insured

27 All data were linked to Medicare and Medicaid claims and pharmaceutical data.

28 , 11 697 900 (16.5%) were dually enrolled in Medicare and Medicaid for at least 1 month.

29 t proportion of patients dually eligible for Medicare and Medicaid had significantly lower MIPS score

30 The Center for Medicare and Medicaid Innovation launched the Bundled Pa

31 ad, mostly because of high overhead in their Medicare and Medicaid managed-care plans.

32 Centers for Medicare and Medicaid Services (CMS) has proposed a rule

33 Over the past decade, the Centers for Medicare and Medicaid Services (CMS) have led the nation

34 ics included compliance with the Centers for Medicare and Medicaid Services (CMS) SEP-1 BCx component

35 Center for Medicare and Medicaid Services data were used to calcula

36 tfolio Online Reporting Tool and Centers for Medicare and Medicaid Services databases were queried fo

37 The cost to the Centers for Medicare and Medicaid Services for eye drops prescribed

38 Food and Drug Administration and Centers for Medicare and Medicaid Services in 2014, whereas CT colon

39 Two options of the Centers for Medicare and Medicaid Services Kidney Care Choices model

40 The Centers for Medicare and Medicaid Services Medicare Part D Prescribe

41 On December 23, 2019, the US Centers for Medicare and Medicaid Services proposed 2 new standards

42 stakeholders and consistent with Centers for Medicare and Medicaid Services TC policies, the COMPASS

43 uate the effects of expansion on Centers for Medicare and Medicaid Services-endorsed Patient Safety I

44 is facility data reported to the Centers for Medicare and Medicaid Services.

45 or healthcare payers, such as the Center for Medicare and Medicaid Services.

46 o 2017 were obtained through the Centers for Medicare and Medicaid Services.

47 d patient transfer data from the Centers for Medicare and Medicaid Services.

48 underused and is not covered by Centers for Medicare and Medicaid Services.PurposeTo report postappr

49 sured patients or patients eligible for both Medicare and Medicaid).

50 Among the Centers for Medicare and Medicaid-linked patients, the HF rehospital

51 haracterizes annual changes in enrollment of Medicare and non-Medicare patients treated at dialysis f

52 Methods Medicare and private payor admissions for isolated CABG

53 Medicaid, $48 million (2.3%) for those with Medicare, and $127 million (6.1%) for those with manufac

54 ng fields of robotics, sensing, personalized medicare, and artificial intelligence.

55 Medicare (aOR, 0.79 [0.72-0.86]), Medicaid (aOR, 0.52 [0

56 In FY2015, Medicare began reducing payments to hospitals with high

57 ed claims data from a 20% national sample of Medicare beneficiaries (2008-2014).

58 ) but less likely to care for more than 1000 Medicare beneficiaries (9.4% vs 17.8%; difference, -8.3

59 pitalizations (17% CAH) for 2 850 194 unique Medicare beneficiaries (mean [SD] age, 76.3 [11.7] years

60 ing was also more likely to be performed for Medicare beneficiaries (OR=2.12, 95% CI 1.08-4.15) than

61 Medicare beneficiaries age 65 to 99 who underwent surger

62 We analyzed Medicare beneficiaries aged >=65 years receiving intrave

63 Setting: population-based; study population: Medicare beneficiaries aged >=65 years who underwent EK

64 Medicare beneficiaries aged >=65 years who underwent end

65 There were 71 017 608 unique Medicare beneficiaries aged 65 years or older (mean age,

66 TICIPANTS: A cross-sectional study involving Medicare beneficiaries aged 65 years or older who underw

67 TS: This retrospective cohort study included Medicare beneficiaries aged 65 years or older who were t

68 ive VE (RVE) of all influenza vaccines among Medicare beneficiaries ages >65 years to prevent influen

69 stigated the RVE of influenza vaccines among Medicare beneficiaries ages >=65 years during the 2018-2

70 in the form of delayed surgery and falls in Medicare beneficiaries awaiting cataract surgery.

71 Although Medicare beneficiaries destined for an inpatient hospita

72 US Medicare beneficiaries diagnosed with dementia are less

73 Models of the cost of sepsis care for Medicare beneficiaries forecast arise approximately 13%

74 Three in 10 Medicare beneficiaries had a preexisting mental illness

75 , we sought to determine whether US minority Medicare beneficiaries had disproportionately low costs

76 study used claims data from fee-for-service Medicare beneficiaries hospitalized for COPD in 2014, at

77 Among fee-for-service Medicare beneficiaries hospitalized for COPD, initiation

78 For rural Medicare beneficiaries hospitalized from 2007 to 2017, C

79 l-cause mortality on an additive scale among Medicare beneficiaries in Massachusetts (2000-2012).

80 Only 1 in 4 CR-eligible Medicare beneficiaries participated in CR and marked dis

81 Among Medicare beneficiaries undergoing an elective HP resecti

82 The number of Medicare beneficiaries undergoing any glaucoma therapeut

83 We analyzed data on elderly Medicare beneficiaries undergoing any of 4 elective inpa

84 Among US Medicare beneficiaries undergoing cataract surgery, thos

85 We studied 30-day mortality among 1,483,074 Medicare beneficiaries undergoing general and orthopedic

86 differences in postoperative outcomes among Medicare beneficiaries undergoing HP procedures.

87 Medicare beneficiaries who are also enrolled in Medicaid

88 Among 1,889,032 Medicare beneficiaries who met inclusion criteria 560,74

89 Among Medicare beneficiaries who underwent a range of surgical

90 Medicare beneficiaries who underwent an elective HP surg

91 Medicare beneficiaries who underwent elective colectomy,

92 We compared the outcomes among ESRD-HD Medicare beneficiaries who were managed with TAVR, surgi

93 The aggregate costs of sepsis care for Medicare beneficiaries will continue to increase.

94 In this article, we use a cohort of Medicare beneficiaries with heart failure with reduced e

95 aracterized by a higher frequency of whites, Medicare beneficiaries, and lower rates of cardiac arres

96 Though bariatric surgery is increasing among Medicare beneficiaries, no long-term, national studies e

97 reat, and presages significant mortality for Medicare beneficiaries.

98 systematically underpredicts costs for frail Medicare beneficiaries.

99 ts to improve the value of care delivered to Medicare beneficiaries.

100 dmission; conventional regression to predict Medicare beneficiary sepsis costs.

101 In addition, the SPAS can be assembled in a medicare brace to record the flexion/extension of joints

102 ch spillovers in the context of a nationwide Medicare bundled payment reform that was implemented in

103 at dialysis onset and had not qualified for Medicare by the fourth dialysis month.

104 rican patients with ESKD become eligible for Medicare by their fourth month of dialysis, some never d

105 Population-based using 2010-2019 Medicare carrier claims.

106 patients vaccinated for influenza among 6735 Medicare-certified facilities operating between 2014 and

107 rospective instrumental variable analysis of Medicare claims (2012-2017) for 30,105 bariatric surgery

108 Medicare claims and IRIS(R) Registry data were used to c

109 tudy of patients >=66 years of age linked to Medicare claims and treated with IV tPA at Get With The

110 railty measure is not directly observed, but Medicare claims data are available.

111 Retrospective analysis of fee-for-service Medicare claims data from 761 acute care hospitals provi

112 NAFLD was identified using Medicare claims data, and controls were selected among p

113 ntific Registry of Transplant Recipients and Medicare claims data, we studied 6780 HCV+ and 139 681 H

114 tals between 2009 and 2015 derived from 100% Medicare claims data.

115 ligible, and actionable cohorts using linked Medicare claims data.

116 llopurinol and febuxostat: a study using the Medicare claims data.

117 tal-level performance metric with the use of Medicare claims data.

118 onal difference-in-difference analysis using Medicare claims from 2013-2017 to evaluate the associati

119 Guidelines-Heart Failure registry linked to Medicare claims.

120 lmologists see fewer patients and have lower Medicare collections.

121 ndex addition is an improvement over current Medicare cost prediction.

122 Whether Medicare costs differ by physician specialty is, to the

123 S-HCC) model to predict patients' annualized Medicare costs in value-based payment programs.

124 ession methods were used to compare observed Medicare costs versus predictions based on the standard

125 ion between the frailty index and annualized Medicare costs was examined, and regression methods were

126 remental cost and effectiveness of extending Medicare coverage for immunosuppressive drugs over the d

127 Extension of immunosuppression Medicare coverage for kidney transplant recipients led t

128 contemporary economic analysis of extending Medicare coverage for the duration of transplant surviva

129 Medicare coverage of immunosuppressant drugs for kidney

130 ding with code-bundling events instituted by Medicare (CT, nuclear imaging, echocardiography).

131 e observational cohort study of 2016 to 2017 Medicare Current Beneficiary Survey data (n=3614) linked

132 Centrality metrics were calculated from 2016 Medicare data and compared to CRE-transfer derived centr

133 Use of Medicare data and failure to account for indirect costs,

134 control patients without appendicitis using Medicare data from 2002 to 2017, examining 54,996 patien

135 The study was implemented using Medicare data from New Jersey and Pennsylvania, and nati

136 This pharmacoepidemiology study uses Medicare data to estimate US prescription fills for anti

137 Medicine using published clinical trial and Medicare data.

138 authors identified 1518 ASRS members in the Medicare database in 2016.

139 ment (LEJR) were identified in the 2016-2017 Medicare database, which was merged with CDC vulnerabili

140 aims data from the MarketScan Commercial and Medicare databases between 1991-2016.

141 Fs with high CRE-derived betweenness but low Medicare-derived betweenness.

142 Medicare does not reimburse for home infusion; patients

143 A total of 94,829 Medicare EK procedures (N = 71,040 unique patients) were

144 sleeve over bypass are preserved across both Medicare elderly and disabled subpopulations.

145 constructed a retrospective cohort of 34 775 Medicare-eligible veterans with group 2/3 PH by linking

146 cially insured patients aged 45-64 years and Medicare enrollees after 2012, although at half the prio

147 Results In almost all instances, Medicare enrollees had the highest utilization rate for

148 insured individuals are similar to those in Medicare enrollees, although at lower rates.

149 on rates have predominantly been reported in Medicare enrollees.

150 by birth year, sex, ethnicity, and length of Medicare enrollment.

151 in a beneficiary's first 3 years of observed Medicare enrollment.

152 verage policy concerns identified by the CMS Medicare Evidence Development and Coverage Advisory Comm

153 ount including trends from 2010 to 2011 when Medicare expanded the allowable number of billing codes

154 of the iStent on the comprehensive glaucoma Medicare expenditure in the same time period warrants fu

155 the contribution of surgical care to overall Medicare expenditures.

156 802 for the hospital, $26 867+/-$14 893, for medicare fee for service and $57 978+/-$29 431 for Medic

157 an hospital margin of -$30 828+/-$39 757 for medicare fee for service and -$6055+/-$45 033 for medica

158 Payer costs were assigned using medicare fee for service national payments, while medica

159 et costs for patients were $2156+/-$1999 for medicare fee for service, and $1658+/-$1250 for medicare

160 18 U.S. dollars, vision-related mortality, a Medicare fee schedule, and CATT (Comparison of Age-Relat

161 Using Medicare fee-for-service 5% claims data from 2007 to 201

162 ive claims for Michigan residents insured by Medicare fee-for-service and Blue Cross Blue Shield of M

163 NDI utilization rates by modality, comparing Medicare fee-for-service and commercially insured enroll

164 PANTS: Serial cross-sectional study of rural Medicare Fee-for-Service beneficiaries admitted to US CA

165 October 1, 2015 and September 30, 2016 among Medicare Fee-for-Service beneficiaries aged >=65 years.

166 ARTICIPANTS: Serial cross-sectional study of Medicare fee-for-service beneficiaries aged 65 years or

167 Among Medicare fee-for-service beneficiaries aged 65 years or

168 We identified Medicare fee-for-service beneficiaries who were CR eligi

169 Contemporary 6-month mortality rates for Medicare fee-for-service beneficiaries with a sepsis inp

170 t Beneficiary Survey data (n=3614) linked to Medicare fee-for-service claims.

171 The study included 453 783 Medicare fee-for-service patients >=65 years of age with

172 Retrospective cohort study of Medicare fee-for-service patients >=65 years with CAD at

173 We analyzed Medicare FFS claims data from surgeons who billed Medica

174 100% Medicare FFS claims from 2013 to 2014 identified older a

175 are FFS claims data from surgeons who billed Medicare for 1 or more of the 293 common procedure codes

176 iversal system, such as that proposed in the Medicare for All Act, has the potential to transform the

177 e savings that would be achieved through the Medicare for All Act, we calculate that a single-payer,

178 ., MI or coronary revascularization), and in Medicare for all-cause mortality.

179 6 [SD, 9.2] years; 54.9% female) enrolled in Medicare for at least 1 month from 2004 through 2017.

180 king national patient-level data from VA and Medicare from 2006 to 2015.

181 ending immunosuppressive drug coverage under Medicare from the current 36 months to the duration of t

182 D patients that were male, older, insured by Medicare, from the highest income quartile, and from the

183 46% had Medicare (government-based insurance coverage for people

184 of adults age >=19 years with commercial or Medicare health insurance who had a history of PAD, CHD,

185 ement in Intermediate-Risk Patients) to 100% Medicare inpatient claims, January 1, 2011, to December

186 We used Medicare inpatient files to identify index admissions fo

187 d younger age, male sex, Medicaid insurance, Medicare insurance, higher number of inpatient and outpa

188 Medicaid or Medicare insurance, surgery at low and medium volume cen

189 is C virus, nonalcoholic steatohepatitis, or Medicare insurance.

190 sant drug coverage compared with a cohort of Medicare-insured transplant recipients, using multivaria

191 AV versus patients with tricuspid AV in the Medicare-linked cohort, whereas no difference was observ

192 45 older patients hospitalized for HF in the Medicare-linked OPTIMIZE-HF (Organized Program to Initia

193 he Centers for Medicare & Medicaid Services' Medicare malpractice geographic practice cost index, and

194 y payer, classified as commercial, Medicaid, Medicare, manufacturer assistance program, or other.

195 Centers for Medicare & Medicaid Services (CMS) eligibility criteria

196 data from the publicly available Centers for Medicare & Medicaid Services (CMS) Inventory Tool to det

197 ed a case definition used by the Centers for Medicare & Medicaid Services and a case definition devel

198 udy of NHs certified by the U.S. Centers for Medicare & Medicaid Services during the 2018-19 influenz

199 Medicare uses the Centers for Medicare & Medicaid Services Hierarchical Condition Cate

200 r of sepsis presentation and the Centers for Medicare & Medicaid Services mandates administration wit

201 ion, criteria in 2014 and either Centers for Medicare & Medicaid Services or Institute for Health Met

202 e 709 cases (95% CI, 694-724) of Centers for Medicare & Medicaid Services sepsis and 1,498 cases (95%

203 The Centers for Medicare & Medicaid Services should consider using the E

204 from malpractice liability, the Centers for Medicare & Medicaid Services' Medicare malpractice geogr

205 Uninsured (aOR 0.41; P = .009) and Medicare/Medicaid (aOR 0.92; P < .001) patients had less

206 llowing payment reform, whereas Hispanic and Medicare/Medicaid dual-eligible patients experienced sli

207 ns who participated in the first year of the Medicare MIPS program, physicians with the highest propo

208 er time compared with those only enrolled in Medicare (nondually enrolled beneficiaries).

209 over 2 years owing the rising enrollments in Medicare offset by the cost of care per admission.

210 re hospitalization, and all-cause mortality (Medicare only) in the 365 days after MI.

211 This study uses Medicare Open Payments data to characterize trends in th

212 ), or government health insurance other than Medicare or Medicaid (43.2%) vs among those without heal

213 reater burden of illness), public insurance (Medicare or Medicaid), residence in a low-income area, a

214 el use included no insurance, insurance with Medicare or Medicaid, and features associated with highe

215 for group 2/3 PH was prior treatment through Medicare (OR, 6.5 [95% CI, 4.9-8.7]).

216 ar year (CY)2012-CY2018, the total number of Medicare Part A/B (fee-for-service) beneficiaries with a

217 subsequent atrial fibrillation diagnosis and Medicare Part A/B/D.

218 of NYS ESRD and non-ESRD patients analyzing Medicare part B billing codes, 7 days before and 3 days

219 IRIS(R) Registry data were used to calculate Medicare Part B expenditures and patient copayments for

220 Total Medicare part B payment for the selected glaucoma proced

221 would result in substantial savings for the Medicare Part B program and for patients receiving anti-

222 lar margin with aflibercept, would result in Medicare Part B savings of $468 million and patient savi

223 Precise costs are not available for Medicare Part C (Medicare Advantage) patients.

224 Medicare sample of patients ages >= 65 with Medicare Part D claims undergoing surgery between Januar

225 Medicare Part D claims were used to extract information

226 e Centers for Medicare and Medicaid Services Medicare Part D Prescriber Public Use Files for 2013, 20

227 We used 100% Medicare Parts A and B and a random 40% sample of Part D

228 We required >1 year of Medicare Parts A and B coverage and >3 years of part D c

229 ative participants who were beneficiaries of Medicare Parts A&B fee-for-service.

230 We evaluated the role of Medicare patient movement between facilities to model th

231 Betweenness of Medicare patient transfers strongly correlated with betw

232 In a subset of 9655 Medicare patients >=65 years old, we compared 1-year adj

233 Less than one-half of Medicare patients achieved a TO following hepatopancreat

234 After 6 months of stable DMARD use, 47.1% of Medicare patients and 39.5% of Optum patients were recei

235 A study of Medicare patients at 340 teaching hospitals (resident-to

236 ative incidence of hospitalized infection in Medicare patients not receiving glucocorticoids was 8.6%

237 all (fee-for-service and Medicare Advantage) Medicare patients to have risen from $27.7 to $41.5 bill

238 al changes in enrollment of Medicare and non-Medicare patients treated at dialysis facilities before

239 In this retrospective analysis of Medicare patients undergoing bariatric surgery, the larg

240 Among Medicare patients undergoing lower extremity joint repla

241 A total of 19,557 Medicare patients underwent an elective colon resection

242 43,007 Medicare patients underwent either pancreas, esophageal,

243 R) Inpatient Files were reviewed to identify Medicare patients who underwent pancreatic and liver pro

244 Medicare patients with coronary artery disease (CAD) hav

245 We identified Fee-For-Service Medicare patients within the 5% enhanced sample file who

246 Among Medicare patients, as admission risk of mortality increa

247 he payment reform-which targeted traditional Medicare patients-had effects of similar magnitude on th

248 -month coverage, from the perspective of the Medicare payer.

249 ent-level claims data from US commercial and Medicare payers, we implemented inclusion and exclusion

250 nt changes in the slope of glaucoma surgical Medicare payment (P < 0.00001) and iStent payment (P < 0

251 increasing burden of quality reporting, the Medicare Payment Advisory (MedPAC) has recommended using

252 This article proposes changes to Medicare payment policy, which currently does not adequa

253 Surgical care has been largely untargeted by Medicare payment reforms because episode costs associate

254 We sought to assess the potential changes in Medicare payments and clinical outcomes of referring hig

255 Complication rates and Medicare payments are significantly lower for high-risk

256 Unadjusted mean Medicare payments for each incremental year of patency w

257 Medicare payments for each surgical episode were calcula

258 There was a discrepancy in Medicare payments for patients who achieved a TO versus

259 Total Medicare payments for surgical care are substantial, rep

260 Baseline Medicare payments per episode for PCI were $20 164 at BP

261 Hospital variation in TO and Medicare payments were analyzed.

262 Medicare payments were compared among patients who achie

263 Average Medicare payments were substantially higher among patien

264 ty-adjusted life year) accrued under current Medicare policy (stroke payment not adjusted for perform

265 population across 477 US cities and for the Medicare population aged 65 years and older across 3,113

266 ause they comprise the poorest subset of the Medicare population; however, it is unclear how their ou

267 ransplant Recipients (SRTR) to study 141 661 Medicare-primary kidney transplant recipients from Janua

268 Medicare program, 2000 to 2008.

269 The Medicare Provider Analysis and Review (MEDPAR) Inpatient

270 We analyzed the Medicare Provider profile to include all U.S. patients u

271 The Medicare Provider Utilization and Payment Data from 2012

272 Medicare recently concluded a national voluntary payment

273 The total raw percent change in Medicare reimbursement rate for each procedure from 2000

274 Lost reimbursement was estimated assuming Medicare reimbursement rates for each procedure based on

275 valuate monetary trends from 2000 to 2018 in Medicare reimbursement rates for the most common general

276 After adjusting for inflation, Medicare reimbursement rates in general surgery have ste

277 Assuming Medicare reimbursement rates, the estimated annual lost

278 Because Medicare reimburses CAHs at cost, CAHs may report fewer

279 To obtain data to inform this concern, Medicare required select surgeons to report on their pos

280 reducing spending seem to be well-aligned in Medicare's bundled payment initiative for bariatric surg

281 Medicare's bundled payments for care improvement-advance

282 The primary outcome was Medicare's cumulative disease-related spending, adjusted

283 ital Association annual survey database, and Medicare's Hospital Compare website.

284 This study uses Medicare's Nursing Home Compare and a university long-te

285 We analyzed claims data from a 20% national Medicare sample of patients ages >= 65 with Medicare Par

286 We used Center for Medicare Services 100% inpatient Limited Data Set (LDS)

287 ions account for billions of dollars in U.S. Medicare spending and are performed by multiple medical

288 (SNFs) assumed accountability for patients' Medicare spending for 90 days from initial SNF admission

289 spital factors, clinical outcomes, and total Medicare spending for the 90-day bariatric surgery episo

290 ve been associated with modest reductions in Medicare spending without apparent compromises in qualit

291 Surgical care accounts for half of all Medicare spending.

292 adults with employer-sponsored insurance or Medicare supplemental plans between 2011 and 2018, befor

293 tral to the CRE transfer network but not the Medicare transfer network; other factors may explain CRE

294 rt study, patients who were beneficiaries of Medicare undergoing their first arteriovenous access pla

295 re matched 1:1:1 based on age, race, time in Medicare, urbanicity of residence, and overall health.

296 Medicare uses the Centers for Medicare & Medicaid Servic

297 d Incentive Payment System (MIPS) is a major Medicare value-based payment program aimed at improving

298 the Health and Retirement Study linked with Medicare, we matched older adults (>=65 years) who under

299 age with government health insurance through Medicare who had a myocardial infarction (MI) hospitaliz

300 ribed PDE5i for PH in the community (through Medicare) will have increased risk of subsequently recei